Aug 01, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Wall Street Analysts See a 44.47% Upside in Omnicell ( OMCL ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Omnicell (OMCL) points to a 44.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Jul 31, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Omnicell ( OMCL ) Beats Q2 Earnings and Revenue Estimates
Omnicell (OMCL) delivered earnings and revenue surprises of +45.16% and +4.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Jul 30, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
Jul 30, 2025 • Zacks Commentary
BULLISH
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell ( OMCL Quick QuoteOMCL - ) and Doximity ( DOCS Quick QuoteDOCS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Jul 28, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Inspire Medical Systems ( INSP ) Expected to Beat Earnings Estimates: Should You Buy?
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jul 24, 2025 • Zacks Commentary
NEUTRAL
Analysts Estimate Omnicell ( OMCL ) to Report a Decline in Earnings: What to Look Out for
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.